Expression of galectin-3 in fine-needle aspirates as a diagnostic marker differentiating benign from malignant thyroid neoplasms
- PMID: 10357421
Expression of galectin-3 in fine-needle aspirates as a diagnostic marker differentiating benign from malignant thyroid neoplasms
Abstract
Background: Galectin-3 is a beta-galactoside-binding protein that has been reported to be expressed preferentially in thyroid malignancies. The current study was designed to substantiate this finding further and to establish a presurgical diagnostic modality of differentiating between benign and malignant thyroid neoplasms by analyzing galectin-3 expression in fine-needle aspirates.
Methods: The expression of galectin-3 was examined immunohistochemically in total of 172 specimens: 45 primary and 20 metastatic papillary carcinomas, 8 primary and 2 metastatic follicular carcinomas, 5 primary and 3 metastatic anaplastic carcinomas, 3 primary medullary carcinomas, 25 follicular adenomas, 3 goiters, and 58 adjacent normal thyroid tissue. Alternatively, epithelial cells were isolated from the fine- needle aspirates of 14 thyroid nodules and subjected to immunoblotting analysis of galectin-3.
Results: Immunohistochemical analysis revealed that all thyroid malignancies of follicular cell origin (including papillary, follicular, and anaplastic carcinomas) showed high and diffuse expression of galectin-3, whereas one of the three medullary carcinomas of parafollicular cell origin displayed weaker and focal expression of galectin-3. In contrast, neither benign thyroid adenomas, goiters, nor normal thyroid tissues expressed galectin-3. Immunoblot analysis of the isolated epithelial cells detected galectin-3 in nine thyroid nodules that were proven histologically to be malignant ( eight papillary carcinomas and one follicular carcinoma) after surgical intervention, whereas galectin-3 was not detected in five nodules proven to be benign follicular adenomas.
Conclusions: Galectin-3 serves as a marker of thyroid malignancy of follicular cell origin. Analysis of galectin-3 expression in fine-needle aspirates enhances the differential diagnostic accuracy between benign and malignant thyroid neoplasms.
Similar articles
-
Galectin-3 does not reliably distinguish benign from malignant thyroid neoplasms.Histopathology. 2004 Nov;45(5):493-500. doi: 10.1111/j.1365-2559.2004.01978.x. Histopathology. 2004. PMID: 15500653
-
Utility of galectin 3 expression in thyroid aspirates as a diagnostic marker in differentiating benign from malignant thyroid neoplasms.Indian J Pathol Microbiol. 2006 Jul;49(3):376-80. Indian J Pathol Microbiol. 2006. PMID: 17001889
-
Differential expression of galectin-1 and galectin-3 in thyroid tumors. Potential diagnostic implications.Am J Pathol. 1995 Sep;147(3):815-22. Am J Pathol. 1995. PMID: 7677193 Free PMC article.
-
[Fine-needle aspiration biopsy of the thyroid nodule: uses and limitations].Nihon Rinsho. 2007 Nov;65(11):2003-7. Nihon Rinsho. 2007. PMID: 18018562 Review. Japanese.
-
[Thyroid nodules--differential diagnosis guidelines].Verh Dtsch Ges Pathol. 1997;81:73-81. Verh Dtsch Ges Pathol. 1997. PMID: 9474857 Review. German.
Cited by
-
Galectin-3: One Molecule for an Alphabet of Diseases, from A to Z.Int J Mol Sci. 2018 Jan 26;19(2):379. doi: 10.3390/ijms19020379. Int J Mol Sci. 2018. PMID: 29373564 Free PMC article. Review.
-
Identification of differentially expressed genes in papillary thyroid cancers.Yonsei Med J. 2009 Feb 28;50(1):60-7. doi: 10.3349/ymj.2009.50.1.60. Epub 2009 Feb 24. Yonsei Med J. 2009. PMID: 19259350 Free PMC article.
-
Improving the prediction of malignancy in cytologically suspicious thyroid nodules.J Endocrinol Invest. 2013 Nov;36(10):843-7. doi: 10.3275/8958. Epub 2013 May 6. J Endocrinol Invest. 2013. PMID: 23656720
-
Expression of galectins in cancer: a critical review.Glycoconj J. 2002;19(7-9):537-42. doi: 10.1023/B:GLYC.0000014083.48508.6a. Glycoconj J. 2002. PMID: 14758077 Review.
-
A preoperative diagnostic test that distinguishes benign from malignant thyroid carcinoma based on gene expression.J Clin Invest. 2004 Apr;113(8):1234-42. doi: 10.1172/JCI19617. J Clin Invest. 2004. PMID: 15085203 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Other Literature Sources
Medical
Research Materials